Work

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)

Year: 2018

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy424.059

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2898124971

FWCI: 0.761

Cites:

Cited by: 9

Related to: 10